IVI’s MISSION is to advance the science and improve the practice of value assessment in healthcare.
IVI’s GOAL is to build a platform that facilitates robust and rigorous patient-centered value assessment of health technologies tailored to the needs and interests of individual decision makers.
The Value Debate
Scientific, technological, and clinical advances are driving a revolution in patient care – but spending on healthcare also continues to increase. Most observers agree that change is needed in order to link healthcare spending to value rather than volume, but determining how to make this link quickly leads to debate and disagreement. What defines value? Value to whom? And how do we measure it?
A New Approach
The Innovation and Value Initiative (IVI) was created to raise the level of discussion regarding value in healthcare and find common ground in the approach to measuring value. The U.S health system is diverse, complex, and ripe for innovation. IVI brings together healthcare leaders from academia, patient advocacy organizations, payers, life sciences companies, providers, delivery systems, and patient communities to advance approaches to value that fit the American context.
Patients are likely to continue to be asked to take more responsibility for their healthcare…it is time to shift the discussion toward helping patients understand what value actually means in choosing their health care and discharging their financial responsibilities.
Jennifer Bright writes in Benefits Pro that employers who rely on health plans and vendors to advise them on coverage for drugs or other treatments need to ask several key questions to ensure they are [...]
IVI has been selected by the Patient-Centered Outcomes Research Institute (PCORI) for a Eugene Washington PCORI Engagement Award. The $50,000 award will be used to convene a multi-stakeholder forum in February 2020 to review established [...]
IVI submitted comments to ICER regarding proposed methodological changes for assessments of the value of single or short-term transformative (SST) therapies. IVI emphasized the need for ICER to address the potential use of its findings [...]
In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use [...]